KRAS and non-small cell lung carcinoma: There is emerging evidence suggesting that the prognostic value of KRAS mutations are modified by the presence of several co-occurring mutations, most notably TP53 and STK11, the two most commonly co-mutated genes in KRAS-driven NSCLC (13, 14).